HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

CPMC Holdings (906.HK) - ORG Can't Afford to Lose, But Baosteel Is a Step Ahead

Ascentage Pharma (6855.HK) Signs $1.3B Deal with Takeda - Finally on the Right Path

Pre-IPO Fangzhou Inc. (PHIP Updates) - Some Points Worth the Attention

Asia Cement (743 HK): $3.22/Share Offer - Really?

Sciclone Pharmaceuticals (6600.HK) - The Privatization Offers a Good Exit Opportunity

China TCM (570.HK) Privatization Update - Investors May Need to Prepare for a Longer Wait

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Event-Driven

<ul>
<li>Since the China/Taiwan situation looks increasingly tense, Xu Xudong/Far Eastern Group may be eager to privatize ACC considering geopolitical conflicts and political risks. Its business is subject to strict regulation.</li>
<li>HK$3.22 Offer Price is disappointing, but the privatization isn't completely impossible (The headcount does not apply now). A certain number of investors are still willing to accept the Offer Price. </li>
<li>For arbitrageurs, the return looks not bad. However, considering the high uncertainties/failure risks, we still advise investors to be cautious. HK$2.5/share is a price point worth participating in.</li>
</ul>


Since the China/Taiwan situation looks increasingly tense, Xu Xudong/Far Eastern Group may be eager to privatize ACC considering geopolitical conflicts and political risks. Its business is subject to strict regulation.
HK$3.22 Offer Price is disappointing, but the privatization isn't completely impossible (The headcount does not apply now). A certain number of investors are still willing to accept the Offer Price. 
For arbitrageurs, the return looks not bad. However, considering the high uncertainties/failure risks, we still advise investors to be cautious. HK$2.5/share is a price point worth participating in.


Asia Cement China (743.HK) Privatization- There May Be "Surprises" Despite Disappointing Offer Price